Tomoki Ikuta

Dr. Tomoki Ikuta

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
GTGen Tamiya
Gen Tamiya
MSMinori Shinya
Minori Shinya
TITadashi Imanishi
Tadashi Imanishi
TITomoki Ikuta
Tomoki Ikuta
SMSatoshi Makino
Satoshi Makino
HIHidetoshi Inoko
Hidetoshi Inoko
A major goal of current human genome-wide studies is to identify the genetic basis of complex disorders. However, the availability of an unbiased, reliable, cost efficient and comprehensive methodology to analyze the entire genome for complex disease association is still largely lacking or problematic. Therefore, we have developed a practical and efficient strategy for whole genome association studies of complex diseases by charting the human genome at 100 kb intervals using a collection of 27 039 microsatellites and the DNA pooling method in three successive genomic screens of independent case–control populations. The final step in our methodology consists of fine mapping of the candidate susceptible DNA regions by single nucleotide polymorphisms (SNPs) analysis. This approach was validated upon application to rheumatoid arthritis, a destructive joint disease affecting up to 1% of the population. A total of 47 candidate regions were identified. The top seven loci, withstanding the most stringent statistical tests, were dissected down to individual genes and/or SNPs on four chromosomes, including the previously known 6p21.3-encoded Major Histocompatibility Complex gene, HLA-DRB1. Hence, microsatellite-based genome-wide association analysis complemented by end stage SNP typing provides a new tool for genetic dissection of multifactorial pathologies including common diseases.

1 August 2004 in Experimental Cell Research
Verified
Journal Article
Closed access
TMTakeharu Minamitani
Takeharu Minamitani
TITomoki Ikuta
Tomoki Ikuta
YSYoshinari Saito
Yoshinari Saito
GTGen Takebe
Gen Takebe
MSMami Sato
Mami Sato
KMKen-Ichi Matsumoto
Ken-Ichi Matsumoto

1 November 2000 in Genes to Cells
Verified
Journal Article
Open access
PDF file
TITomoki Ikuta
Tomoki Ikuta
HAHiroyoshi Ariga
Hiroyoshi Ariga
KMKen‐Ichi Matsumoto
Ken‐Ichi Matsumoto
An extracellular matrix tenascin‐X (TNX) is highly expressed in muscular tissues, especially heart and skeletal muscle, and is also prominent around blood vessels. The precise in vivo role of TNX remains to be elucidated. To identify proteins that interact with TNX in the extracellular environment, we searched for TNX‐binding proteins using a yeast two‐hybrid system.We used mouse TNX‐specific fibronectin type III repeats (mTNX/FNIII13‐25) as a bait for the screening. We found that vascular endothelial growth factor B (VEGF‐B) binds to mTNX/FNIII13‐25. This interaction was confirmed by pull‐down assays and co‐immunoprecipitation assays. The full‐length mTNX, as well as mTNX/FNIII13‐25, interacted with both alternative splice isoforms VEGF‐B186 and VEGF‐B167. Furthermore, the full‐length mTNX also bound to VEGF‐A. The minimal region of TNX that interacts with VEGF‐B was mapped to the FNIII repeats (FNIII13‐25) but not to the other characteristic domains of TNX. The TNX‐binding site of VEGF‐B was located in the N‐terminal 115‐amino acid region. mTNX/FNIII13‐25 did not prevent the interaction of VEGF‐B with VEGFR‐1 (VEGF receptor 1), and VEGF‐B could simultaneously bind to both mTNX/FNIII13‐25 and VEGFR‐1. A conditioned medium from transfected 293T cells coexpressing full‐length TNX and VEGF‐B could promote DNA synthesis in bovine endothelial cells in which VEGFR‐1 were expressed. VEGFR‐1 phosphorylation triggered by VEGF‐B186 were increased in cells plated with mTNX/FNIII13‐25 or full‐length mTNX, compared with cells plated with VEGF‐B186 alone.TNX interacts with VEGF‐B and enhances the ability of VEGF‐B to stimulate cell proliferation. This enhanced mitogenecity is caused by increased signals mediated by the VEGFR‐1 receptor. This finding suggests a role for TNX in the regulation of the development of blood vessels such as vasculogenesis and angiogenesis.

1 September 1998 in Gene
Verified
Journal Article
Closed access
TITomoki Ikuta
Tomoki Ikuta
NSNorio Sogawa
Norio Sogawa
HAHiroyoshi Ariga
Hiroyoshi Ariga
TIToshimichi Ikemura
Toshimichi Ikemura
KMKen-Ichi Matsumoto
Ken-Ichi Matsumoto

17 December 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konno
Hiroyuki Konno
YKYoshiaki Kanai
Yoshiaki Kanai
MKMikiyuki Katagiri
Mikiyuki Katagiri
TWTami Watanabe
Tami Watanabe
AMAkemi Mori
Akemi Mori
Takuji ShirasawaTakuji Shirasawa
Takuji Shirasawa
Melinjo (Gnetum gnemonL.) seed extract (MSE) containingtrans-resveratrol (3,5,4′-trihydroxy-trans-stilbene) and other derivatives exerts various beneficial effects. However, its mechanism of action in humans remains unknown. In this study, we aimed to investigate beneficial effects of MSE in healthy adult males. In this double-blind, randomized controlled study, 30 males aged 35–70 years with ≤10% flow-mediated dilatation received placebo or 750 mg MSE powder for 8 weeks, and twenty-nine males (45.1±8.8years old) completed the trial. There was a significant difference in the melinjo and placebo groups. Compared with the placebo control, MSE significantly reduced serum uric acid at 4 weeks and 8 weeks (n=14and 15, resp.). HDL cholesterol was significantly increased in the melinjo group. To clarify the mechanism of MSE for reducing uric acid, we investigated xanthine oxidase inhibitory activity, angiotensin II type 1 (AT1) receptor binding inhibition rate, and agonistic activities for PPARαand PPARγ. MSE,trans-resveratrol, and a resveratrol dimer, gnetin C (GC), significantly inhibit AT1 receptor binding and exhibit mild agonistic activities for PPARαand PPARγ. In conclusion, MSE may decrease serum uric acid regardless of insulin resistance and may improve lipid metabolism by increasing HDL cholesterol.

25 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YMYusuke Matsuno
Yusuke Matsuno
YAYuko Atsumi
Yuko Atsumi
ALAlauddin
Alauddin
Md Masud RanaMd Masud Rana
Md Masud Rana
HFHaruka Fujimori
Haruka Fujimori
KYKen-Ichi Yoshioka
Ken-Ichi Yoshioka
Genomic destabilisation is associated with the induction of mutations, including those in cancer-driver genes, and subsequent clonal evolution of cells with abrogated defence systems. Such mutations are not induced when genome stability is maintained; however, the mechanisms involved in genome stability maintenance remain elusive. Here, resveratrol (and related polyphenols) is shown to enhance genome stability in mouse embryonic fibroblasts, ultimately protecting the cells against the induction of mutations in the ARF/p53 pathway. Replication stress-associated DNA double-strand breaks (DSBs) that accumulated with genomic destabilisation were effectively reduced by resveratrol treatment. In addition, resveratrol transiently stabilised the expression of histone H2AX, which is involved in DSB repair. Similar effects on the maintenance of genome stability were observed for related polyphenols. Accordingly, we propose that polyphenol consumption can contribute to the suppression of cancers that develop with genomic instability, as well as lifespan extension.